Phase I/II Trial of Adeno-Associated Virus–Mediated Alpha-Glucosidase Gene Therapy to the Diaphragm for Chronic Respiratory Failure in Pompe Disease: Initial Safety and Ventilatory OutcomesBarbara K. Smith, Barry J. Byrne, Shelley Collins et al.|Human Gene Therapy|2013Cited by 156
Preclinical Potency and Safety Studies of an AAV2-Mediated Gene Therapy Vector for the Treatment of <i>MERTK</i> Associated Retinitis PigmentosaThomas J. Conlon, William W. Hauswirth, Wen‐Tao Deng et al.|Human Gene Therapy Clinical Development|2013Cited by 95
Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical PlanningManuela Corti, Barry J. Byrne, Brian Cleaver et al.|Human Gene Therapy Clinical Development|2015Cited by 93
Pompe disease gene therapyBarry J. Byrne, Cathryn Mah, Darin J. Falk et al.|Human Molecular Genetics|2011Cited by 93
Phase I/II Trial of Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV1-CMV- <i>GAA</i> ) Gene Vector in Patients with Pompe DiseaseBarry J. Byrne, Shelley Collins, Barbara K. Smith et al.|Human Gene Therapy Clinical Development|2014Cited by 45